My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Avidity Biosciences, Inc. - Common Stock (NQ:RNA)

71.87 -0.10 (-0.14%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Avidity Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

How A First-Ever In Gene Silencing Catapulted Avidity Biosciences Into The Stratosphere ↗

December 14, 2022

The company tested its efforts in myotonic dystrophy 1, a form of muscular dystrophy.

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 14, 2022

Via Benzinga

Avidity Biosciences Shares Gain On Encouraging Data From Early-Stage Myotonic Dystrophy Trial ↗

December 14, 2022

Via Benzinga

REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday ↗

December 14, 2022

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

What's Going On With Avidity Biosciences Stock? ↗

December 14, 2022

Avidity Biosciences Inc (NASDAQ: RNA) shares are trading higher Wednesday after the company announced positive data demonstrating the first-ever successful

Via Benzinga

Recap: Avidity Biosciences Q2 Earnings ↗

August 09, 2022

Avidity Biosciences (NASDAQ:RNA) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

What 4 Analyst Ratings Have To Say About Avidity Biosciences ↗

July 20, 2022

Avidity Biosciences (NASDAQ:RNA) has observed the following analyst ratings within the last quarter:

Via Benzinga

Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories" ↗

July 20, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 14, 2022

Via Benzinga

AiViva's Diverse Product Pipeline Could Have The Potential To Transform Unmet Medical Needs ↗

November 21, 2022

AiViva BioPharma is a clinical-stage biotech company developing innovative and transformative treatments and products to address unmet medical needs for a wide array of diseases.

Via Benzinga

Short Interest Sector Focus: Healthcare Sector ↗

October 20, 2022

As of the close of business on Wednesday, 10/19, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector...

Via Benzinga

Nasdaq Turns Higher; Crude Oil Rises Over 2% ↗

September 27, 2022

U.S. stocks pared some losses toward the end of trading, with the Nasdaq Composite turning higher on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 27, 2022

Gainers

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

May 11, 2022

On Wednesday, 807 companies reached new 52-week lows.

Via Benzinga

Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday ↗

September 28, 2022

Gainers

Via Benzinga

Avidity Biosciences, Kronos Worldwide And Some Other Big Stocks Moving Lower On Tuesday ↗

September 27, 2022

U.S. stocks traded lower, with the Dow Jones dropping around 180 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

US Stocks Turn Lower; Dow Dips 175 Points ↗

September 27, 2022

U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 175 points on Tuesday.

Via Benzinga

Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session ↗

September 27, 2022

Gainers

Via Benzinga

US Stocks Open Higher; Dow Surges 300 Points ↗

September 27, 2022

U.S. stocks traded higher this morning, with the Dow Jones gaining around 300 points on Tuesday.

Via Benzinga

Highly Rated Avidity Biosciences Hammered After Side Effect Sidelines Study ↗

September 27, 2022

The stock has a high IBD Digital rating, but plummeted on the news.

Via Investor's Business Daily

FDA Slaps Clinical Hold On Avidity's Early-Stage Myotonic Dystrophy Trial ↗

September 27, 2022

The FDA has placed a partial clinical hold on new participant enrollment in Avidity Biosciences Inc's (NASDAQ: RNA) Phase 1/2 MARINA trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 27, 2022

Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock moved upwards by 22.8% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $65.8 million.

Via Benzinga

Short Interest Sector Focus: Healthcare Sector ↗

September 26, 2022

As of the close of business on Friday, 9/23, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector...

Via Benzinga

7 Unknown Biotech Stocks That Could Rocket in 2023 ↗

September 23, 2022

Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline.

Via InvestorPlace

Short Interest Sector Focus: Healthcare Sector ↗

August 30, 2022

As of the close of business on Monday, 8/29, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗

July 20, 2022

Upgrades

Via Benzinga

Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew ↗

July 12, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022 ↗

July 12, 2022

Upgrades

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 11, 2022

Gainers Novo Integrated Sciences (NASDAQ:NVOS) shares increased by 21.7% to $2.3 during Monday's after-market session. The market value of their outstanding shares is at $68.8 million.

Via Benzinga

Avidity Biosciences Earnings Perspective: Return On Capital Employed ↗

June 14, 2022

According to data from Benzinga Pro, during Q1, Avidity Biosciences's (NASDAQ:RNA) reported sales totaled $1.79 million. Despite a 11.17% increase in earnings, the company posted a loss of $34.23...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.